Zai Lab

Zai Lab(ZLAB)

CA - South SF
Biotechnology
WebsiteLinkedInCareers Page

Focus: Small Molecules

Zai Lab is a life sciences company focused on Small Molecules.

OncologyImmunologyNephrologyInfectious DiseasesEndocrinology
Funding Stage
PUBLIC
Total Funding
$858M
Open Jobs
0

Products & Portfolio (4)

MEDROXYPROGESTERONE ACETATE
medroxyprogesterone acetate
Post-LOE
INJECTION · INJECTABLE
2004
30
METHYLPREDNISOLONE ACETATE
methylprednisolone acetate
Post-LOE
INJECTION · INJECTABLE
2005
30
XENLETA
lefamulin acetate
Peak
INTRAVENOUS · SOLUTION
2019
0
XENLETA
lefamulin acetate
Peak
ORAL · TABLET
2019
0

Pipeline & Clinical Trials

NovoTTF-100L
Gastric Cancer
N/A
Clinical Trials (1)
NCT04281576Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
N/A
ZL-1310
SCLC
Phase 1
Clinical Trials (1)
NCT06179069A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT04653038A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
Phase 1
Phase 1
Clinical Trials (1)
NCT05859464A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT04257617A Trial of ZL-1201 in Subjects With Advanced Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT07374848Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
Phase 1
Margetuximab Margetuximab-IV
HER2 Positive Metastatic Breast Cancer
Phase 1
Clinical Trials (1)
NCT04398108A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC
Phase 1
Phase 1
Clinical Trials (1)
NCT05263986The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT07235384A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
Phase 1
Phase 1
Clinical Trials (1)
NCT02397005Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects
Phase 1
Phase 1
Clinical Trials (1)
NCT05065710A Study of ZL-1211 in Patients With Advanced Solid Tumor
Phase 1
Niraparib combined with MGD013
Gastric Cancer
Phase 1
Clinical Trials (1)
NCT04178460A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
Phase 1
Phase 1
Clinical Trials (1)
NCT03551171The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer
Phase 1
Moxifloxacin Oral Tablet
Healthy Volunteer
Phase 1
Clinical Trials (1)
NCT06462326A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers
Phase 1
Tisotumab Vedotin
Solid Malignancies
Phase 1
Clinical Trials (1)
NCT05866354To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
Phase 1
Phase 1/2
Clinical Trials (1)
NCT04212221MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT06885281A Study of ZL-1310 in Participants With Selected Solid Tumors
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT03093116A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Phase 1/2
Bemarituzumab
Gastric Cancer
Phase 2
Clinical Trials (1)
NCT03694522A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
Phase 2
Phase 2
Clinical Trials (1)
NCT04262804A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
Phase 2
Phase 2
Clinical Trials (1)
NCT05385068A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi
Phase 2
ZL-3101
Eczema
Phase 2
Clinical Trials (1)
NCT03134352Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema
Phase 2
Phase 2
Clinical Trials (1)
NCT03516071A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
Phase 2
efgartigimod IV
Lupus Nephritis
Phase 2
Phase 2
Clinical Trials (1)
NCT04716686Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Phase 2
Phase 2
Clinical Trials (1)
NCT04282980A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
Phase 2
efgartigimod IV
Membranous Nephropathy
Phase 2
Phase 2
Clinical Trials (1)
NCT05130515Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.
Phase 2
Phase 2
Clinical Trials (1)
NCT04633122A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Phase 2
Phase 2
Clinical Trials (1)
NCT04217798Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer
Phase 2
ZL-1102 1% w/w gel BID for 16 weeks
Plaque Psoriasis
Phase 2
Clinical Trials (1)
NCT06380907A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis
Phase 2
Phase 2
Clinical Trials (1)
NCT04392102A Study of Niraparib in Patients With Relapsed Ovarian Cancer
Phase 2
Phase 2/3
Clinical Trials (1)
NCT07204275A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Phase 2/3
margetuximab
Gastric Cancer
Phase 2/3
Clinical Trials (1)
NCT04082364Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
Phase 2/3
Phase 3
Clinical Trials (1)
NCT06140836A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Phase 3
Phase 3
Clinical Trials (1)
NCT03705156Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient
Phase 3
Phase 3
Clinical Trials (1)
NCT03709316A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
Phase 3
Xanomeline and Trospium Chloride Capsules
Schizophrenia
Phase 3
Clinical Trials (1)
NCT05919823A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
Phase 3
Bemarituzumab
Gastric Cancer
Phase 3
Phase 3
Clinical Trials (1)
NCT07218146A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Phase 3
Phase 3
Clinical Trials (1)
NCT06162286A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP
Phase 3
Phase 3
Clinical Trials (1)
NCT07211776A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
Phase 3
Phase 3
Clinical Trials (1)
NCT03516084A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2024
Portfolio: 4 approved products, 40 clinical trials
Top TAs: Oncology, Immunology, Endocrinology
Publications: 25 in PubMed
SEC Filings: 2 available
Portfolio Health
Peak2 (50%)
Post-LOE2 (50%)
4 total products
Therapeutic Area Focus
Oncology
29 pipeline
Immunology
3 pipeline
Endocrinology
1 pipeline
Neurology
1 pipeline
Respiratory
1 pipeline
Nephrology
1 pipeline
Marketed
Pipeline

Financials (FY2025)

Revenue
$267M24%
R&D Spend
$266M(100%)7%
Net Income
-$335M
Cash
$450M
Source: SEC 10-K Filing